Nothing Special   »   [go: up one dir, main page]

CA2168091A1 - Croissance in vitro de precurseurs neutrophiles et de precurseurs de megacaryocytes dans un milieu exempt de serum - Google Patents

Croissance in vitro de precurseurs neutrophiles et de precurseurs de megacaryocytes dans un milieu exempt de serum

Info

Publication number
CA2168091A1
CA2168091A1 CA002168091A CA2168091A CA2168091A1 CA 2168091 A1 CA2168091 A1 CA 2168091A1 CA 002168091 A CA002168091 A CA 002168091A CA 2168091 A CA2168091 A CA 2168091A CA 2168091 A1 CA2168091 A1 CA 2168091A1
Authority
CA
Canada
Prior art keywords
cells
serum
free
megakaryocyte
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002168091A
Other languages
English (en)
Inventor
Stephen L. Smith
Xiaoying Qiao
Susan M. Maciukas
James G. Bender
Dennis E. Van Epps
Maureen F. Loudovaris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexell Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2168091A1 publication Critical patent/CA2168091A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/98—Xeno-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

On décrit des compositions de milieux exempts de sérum et de protéines animales, devant être utilisées conjointement avec des facteurs de croissance hématopoiétique pour la croissance in vitro de précurseurs de neutrophiles et de mégacaryocytes humains. Le milieu est composé d'un milieu de base, d'un corticostéroïde, de transferrine, d'insuline, de cholestérol, d'éthanolamine et d'albumine humaine. L'invention concerne également des procédés de préparation de suspensions, exemptes de sérum et de protéines, animales, de cellules précurseurs hématopoiétiques humaines, dans lesquelles le composant cellulaire comprend au moins 16 % environ de précurseurs de neutrophiles et au moins 1 % environ de précurseurs de mégacaryocytes. On décrit des suspensions exemptes de sérum et de protéines, animales, dans lesquelles le composant cellulaire comprend au moins 30 % environ, et de préférence plus de 60 % de précurseurs de neutrophiles. Les précurseurs de neutrophiles comprennent des cellules blastiques, des promyélocytes, des myélocytes neutrophiles et des métamyélocytes neutrophiles. On décrit également des suspensions de cellules exemptes de sérum et de protéines, animales, dans lesquelles le composant cellulaire comprend au moins 3 % environ et de préférence plus de 8 % de précurseurs de mégacaryocytes, ainsi que des suspensions de cellules exemptes de sérum et de protéines animales, dans lesquelles le composant cellulaire comprend des unités formant des colonies et des unités formant des grappes.
CA002168091A 1993-08-23 1994-08-23 Croissance in vitro de precurseurs neutrophiles et de precurseurs de megacaryocytes dans un milieu exempt de serum Abandoned CA2168091A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11027793A 1993-08-23 1993-08-23
US08/110,277 1993-08-23

Publications (1)

Publication Number Publication Date
CA2168091A1 true CA2168091A1 (fr) 1995-03-02

Family

ID=22332160

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002168091A Abandoned CA2168091A1 (fr) 1993-08-23 1994-08-23 Croissance in vitro de precurseurs neutrophiles et de precurseurs de megacaryocytes dans un milieu exempt de serum

Country Status (7)

Country Link
EP (1) EP0719326A1 (fr)
JP (1) JPH09505462A (fr)
AU (1) AU702871B2 (fr)
CA (1) CA2168091A1 (fr)
IL (1) IL110755A (fr)
SG (1) SG52619A1 (fr)
WO (1) WO1995006112A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4213827A4 (fr) * 2020-09-21 2024-10-23 Antares Pharma Inc Formulation pharmaceutique aqueuse de phosphate de sodium d'hydrocortisone et de monothioglycérol

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US6248319B1 (en) 1989-10-16 2001-06-19 Krisztina M. Zsebo Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
US6852313B1 (en) 1989-10-16 2005-02-08 Amgen Inc. Method of stimulating growth of melanocyte cells by administering stem cell factor
US6207454B1 (en) 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US9068164B1 (en) * 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
AU6125396A (en) * 1995-06-07 1996-12-30 Novartis Ag Serum-free media for primitive hematopoietic cells and metho ds of use thereof
AU2260097A (en) * 1996-03-12 1997-10-01 Life Technologies, Inc. Hematopoietic cell culture nutrient supplement
EP2221361A3 (fr) 1996-08-30 2011-02-09 Life Technologies Corporation Méthode de production d'un polypeptide in vitro dans une cellule de mammifère dans un milieu de culture sans sérum and sans protéines
US5945337A (en) 1996-10-18 1999-08-31 Quality Biological, Inc. Method for culturing CD34+ cells in a serum-free medium
US6811776B2 (en) 2000-12-27 2004-11-02 The Regents Of The University Of Michigan Process for ex vivo formation of mammalian bone and uses thereof
DE602004026917D1 (de) * 2003-12-26 2010-06-10 Makoto Asashima Basalmedium zur kultivierung von es-zellen
JP4651282B2 (ja) * 2004-01-21 2011-03-16 田辺三菱製薬株式会社 造血幹細胞及び造血前駆細胞の増幅方法
US7923013B2 (en) 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
US7534434B2 (en) 2004-12-28 2009-05-19 The Rockefeller University Glycolipids and analogues thereof as antigens for NK T cells
US7837990B2 (en) 2005-03-28 2010-11-23 The Rockefeller University In vivo expanded NKT cells and methods of use thereof
CA2647201C (fr) 2006-03-24 2016-03-08 Children's Medical Center Corporation Procede permettant de moduler la croissance de cellules souches hematopoietiques
AU2015207905B2 (en) * 2006-03-24 2017-04-27 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
AU2013202353B2 (en) * 2006-03-24 2015-05-07 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
EP3824885A1 (fr) 2006-10-20 2021-05-26 Children's Medical Center Corporation Procédé pour améliorer la régénération tissulaire
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9051548B2 (en) 2009-02-03 2015-06-09 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
JP2014523741A (ja) * 2011-07-06 2014-09-18 セレラント セラピューティクス インコーポレイテッド 血小板産生のための巨核球前駆細胞
WO2013082241A2 (fr) 2011-12-02 2013-06-06 Fate Therapeutics, Inc. Méthodes améliorées permettant de traiter l'ischémie
ES2836976T3 (es) 2011-12-02 2021-06-28 Fate Therapeutics Inc Composición mejorada de células madre
ES2688019T3 (es) * 2012-06-05 2018-10-30 The Regents Of The University Of California Métodos y composiciones para la producción acelerada de células epiteliales pigmentadas retinianas a partir de células pluripotentes
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
JP7521738B2 (ja) * 2020-05-18 2024-07-24 キヤノン株式会社 目的細胞の生産方法、目的細胞による生産物の生産方法、および無血清培地
FR3128874A1 (fr) * 2021-11-09 2023-05-12 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
AU639378B2 (en) * 1990-10-05 1993-07-22 Systemix, Inc. Megakaryocyte and platelet growth, production and composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4213827A4 (fr) * 2020-09-21 2024-10-23 Antares Pharma Inc Formulation pharmaceutique aqueuse de phosphate de sodium d'hydrocortisone et de monothioglycérol

Also Published As

Publication number Publication date
AU7674494A (en) 1995-03-21
JPH09505462A (ja) 1997-06-03
AU702871B2 (en) 1999-03-11
SG52619A1 (en) 1998-09-28
WO1995006112A1 (fr) 1995-03-02
IL110755A0 (en) 1994-11-11
EP0719326A1 (fr) 1996-07-03
IL110755A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
US6037174A (en) Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
AU702871B2 (en) (In vitro) growth of neutrophil and megakaryocyte precursors in serum-free media
US6241984B1 (en) Human hematopoietic progenitor cell preparations and their expansion in a liquid medium
Debili et al. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors
US5744361A (en) Expansion of human hematopoietic progenitor cells in a liquid medium
Sitnicka et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells
Sandstrom et al. Effects of CD34+ cell selection and perfusion on ex vivo expansion of peripheral blood mononuclear cells
US6733746B2 (en) Hematopoietic cell culture nutrient supplement
Wada et al. Expression of major blood group antigens on human erythroid cells in a two phase liquid culture system
US6667034B2 (en) Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture, methods for assaying the effect of substances on lineage-specific cell production, and cell compositions produced by these cultures
WO1996040866A1 (fr) Milieux sans serum pour des cellules hematopoietiques primaires et procedes d'utilisation
US5955357A (en) In-vitro-derived human neutrophil precursor cells
JPH08509377A (ja) ヒトのエリスロイド前駆細胞集団
Mazur et al. Isolation of large numbers of enriched human megakaryocytes from liquid cultures of normal peripheral blood progenitor cells
US5846529A (en) Infusion of neutrophil precursors for treatment of neutropenia
US5888499A (en) Method for increasing neutrophil populations using in vitro-derived human neutrophil precursor cells
Smith et al. Neutrophil maturation of CD34+ cells from peripheral blood and bone marrow in serum-free culture medium with PIXY321 and granulocyte-colony stimulating factor (G-CSF)
Hirao et al. Synergism of interleukin 12, interleukin 3 and serum factor on primitive human hematopoietic progenitor cells
Cohen et al. Ex Vivo Expanded (EVE) Megakaryocytes (MK) for Supportive Care of Patients with Breast Cancer Hematologic Malignancies: A Phase I/II Clinical Study
WO1999000486A1 (fr) Compositions et procedes permettant d'induire la croissance et la differenciation de cellules souches hematopietiques
EP0675726A1 (fr) Croissance, production et composition des megacaryocytes et des thrombocytes
Zandstra Cytokine-dependent regulation of human hematopoietic cell self-renewal and differentiation in suspension cultures

Legal Events

Date Code Title Description
FZDE Discontinued